Rituximab Biosimilar 500mg Injection – Latest Update for Global Buyers
Cordium Pharmaceuticals Pvt Ltd is a leading global exporter based in India, supplying high-quality Rituximab Biosimilar 500mg Injection to international markets with fast and reliable delivery. We ensure timely shipments to the United States, Germany, United Kingdom, Netherlands, South Africa, United Arab Emirates, and Brazil.
Rituximab Biosimilar is widely used in the treatment of various cancers and autoimmune conditions. Manufactured under strict quality standards, it offers a cost-effective and equally effective alternative to branded biologics.
🔹 Uses of Rituximab Biosimilar 500mg Injection
Rituximab is a monoclonal antibody used for:
Non-Hodgkin’s Lymphoma (NHL)
Chronic Lymphocytic Leukemia (CLL)
Rheumatoid Arthritis (RA)
Granulomatosis with Polyangiitis
Other autoimmune disorders
It works by targeting CD20 proteins on B-cells, helping the immune system eliminate abnormal or cancerous cells.
🔹 Dosage & Administration
Administered as an intravenous (IV) infusion under medical supervision
Dosage depends on patient condition, body surface area, and treatment protocol
Typically given in cycles as prescribed by an oncologist or healthcare provider
Pre-medication may be required to reduce infusion-related reactions
🔹 Possible Side Effects
Common side effects may include:
Fever, chills, or infusion reactions
Fatigue and weakness
Nausea or headache
Low blood cell counts
Increased risk of infections
Serious side effects are rare but may include severe allergic reactions or infections. Always consult a healthcare professional before use.
🌍 Why Choose Cordium Pharmaceuticals Pvt Ltd?
Trusted global exporter from India
Competitive pricing on oncology medicines
Assured quality and compliance standards
Fast international delivery network
Dedicated customer support
📦 Fast Global Delivery Available In:
United States | Germany | United Kingdom | Netherlands | South Africa | UAE | Brazil
📞 Contact for Orders & Enquiries:
WhatsApp: +91-9405117673
Email: info@cordiumpharma.com
